Uploaded March 2026 | Updated September 2026, 3 days ago
Type 1 diabetes research took centre stage at the 61st EASD Annual Meeting in Vienna.
In this discussion, Prof. Chantal Mathieu and Prof. Francesco Dotta explore the results of two major clinical trials conducted through the INNODIA consortium: the VERA-T1D and MELD-ATG studies.
The VERA-T1D trial investigated verapamil, a long-standing cardiovascular drug, as a therapy to preserve beta cell function in adults with newly diagnosed type 1 diabetes. Although the study narrowly missed statistical significance for its primary endpoint, the findings provide valuable insights into disease heterogeneity and future treatment strategies. The MELD-ATG trial used an adaptive clinical trial design to test multiple doses of anti-thymocyte globulin (ATG), identifying a low dose that may delay beta-cell destruction with fewer side effects. Together, these studies highlight the growing momentum behind disease-modifying therapies and precision medicine in type 1 diabetes.
Watch the full conversation to learn what these results mean for the future of type 1 diabetes treatment.
Type 1 diabetes research took centre stage at the 61st EASD Annual Meeting in Vienna.
In this discussion, Prof. Chantal Mathieu and Prof. Francesco Dotta explore the results of two major clinical trials conducted through the INNODIA consortium: the VERA-T1D and MELD-ATG studies.
The VERA-T1D trial investigated verapamil, a long-standing cardiovascular drug, as a therapy to preserve beta cell function in adults with newly diagnosed type 1 diabetes. Although the study narrowly missed statistical significance for its primary endpoint, the findings provide valuable insights into disease heterogeneity and future treatment strategies. The MELD-ATG trial used an adaptive clinical trial design to test multiple doses of anti-thymocyte globulin (ATG), identifying a low dose that may delay beta-cell destruction with fewer side effects. Together, these studies highlight the growing momentum behind disease-modifying therapies and precision medicine in type 1 diabetes.
Watch the full conversation to learn what these results mean for the future of type 1 diabetes treatment.
